Latest news
Toward More Precise Classification of HER2 Mutations in NSCLC – Lung Cancer Europe - OncodailyOncodaily · Sat, 08 Aug 2026 18:58:03 GMTHER2 Mutations in NSCLC: Critical Risks of Outdated Terms - OncodailyOncodaily · Fri, 07 Aug 2026 16:43:17 GMTCommunity Adoption of Frontline Combination Regimens and Tolerability - onclive.comonclive.com · Fri, 07 Aug 2026 03:26:14 GMTBeyond the Approval: Operationalizing Zongertinib for HER2-Mutant Lung Cancer - Pharmacy TimesPharmacy Times · Wed, 05 Aug 2026 15:22:02 GMTEGFR Amplification in EGFR-Mutated NSCLC: Critical Risk Marker - OncodailyOncodaily · Wed, 05 Aug 2026 14:17:49 GMTBenjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies - The ASCO PostThe ASCO Post · Wed, 05 Aug 2026 00:47:22 GMTTP53 Co-Mutation Background and the TOP Study Design and Results - onclive.comonclive.com · Thu, 30 Jul 2026 16:13:08 GMTLeptomeningeal Disease Management in EGFR-Mutated NSCLC: Systemic Therapy, Radiation, and Intrathecal Options - onclive.comonclive.com · Tue, 28 Jul 2026 13:32:05 GMT